Corona Remedies IPO Opens: Key Details & Strong GMP
Corona Remedies IPO subscription starts Dec 8. Price band ₹1008-1062, aims to raise ₹655 cr. Grey market premium signals strong investor interest. Details inside.
Corona Remedies IPO subscription starts Dec 8. Price band ₹1008-1062, aims to raise ₹655 cr. Grey market premium signals strong investor interest. Details inside.
Senior US State Department official Allison Hooker and trade negotiators arrive in India to strengthen economic ties, discuss tariffs, and foster AI and space collaboration. Key meetings scheduled in New Delhi and Bengaluru.
Corona Remedies' ₹655 crore IPO opens today. With a price band of ₹1,008-₹1,062 and a strong GMP, analysts give a 'Subscribe for long term' rating. Key dates and details inside.
Odisha's new Pharma & Medtech Policy 2025 aims to make the state a strategic hub for healthcare manufacturing. The policy includes plans for dedicated industrial parks and a roadmap aligned with India's 2047 vision. Read more.
India and Russia deepen strategic ties, signing agreements in trade, energy, and tech, aiming for $100 billion trade by 2030. Can this offset US tariff pressures?
Himachal Pradesh's pharmaceutical hub is in turmoil as 38 firms lose WHO-GMP certification, raising serious quality concerns. Discover the causes and impact.
Nivin Pauly's OTT debut 'Pharma' trailer reveals a medical rep exposing dangerous drugs. The series premieres on JioCinema December 19 in 7 languages. Read more.
Anna Haakenson's viral Instagram post details 9 cultural contrasts between India and the US after a 2.5-month family trip. Discover the insights sparking global discussion.
Hyderabad's Laurus Labs plans aggressive CDMO growth, targeting 50% of revenue in five years. CEO Dr. Satyanarayana Chava reveals strategy focusing on cell & gene therapy and global expansion. Read more.
Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.
Corona Remedies IPO opens Dec 8, 2025, to raise ₹655.37 crore. Check price band, GMP, financials, and key dates for this pharma company's public issue.
As Putin visits India, the world watches how New Delhi will balance discounted Russian oil, defence needs, and US pressure. Will India secure its autonomy or face new sanctions?
Russian President Vladimir Putin aims to elevate cooperation with India to a new level during his Dec 4-5 visit. Defence deals like S-400, Su-57 jets & nuclear energy pacts to dominate talks.
Indian stock markets opened strong on December 3, 2025, with Nifty crossing 25,400. Key stocks like TCS and Sun Pharma in focus. Read for full analysis and trading cues.
Wockhardt's share price surged over 6% after the USFDA accepted its New Drug Application for Zaynich, a novel antibiotic. Discover the details and market impact.
Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.
India's tourism sector sees a strong recovery, with the US, UK, and Canada among the top contributors. Discover the full list and key insights from the latest 2024-25 data.
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
November 2025 witnessed 9 IPOs with 12 listings. Groww leads with 58.85% gains while experts warn of investor fatigue and unrealistic valuations. Read full analysis.
Sudeep Pharma shares surged 33.78% in market debut, exceeding expectations. Analysts advise partial profit booking while maintaining long-term optimism. Read expert views on buy/sell strategy.
Sudeep Pharma shares surged 23% in stock market debut today, outperforming grey market expectations. The ₹895-crore IPO was subscribed 93.71 times. Read full analysis.
Sudeep Pharma makes its stock market debut today. With a GMP of ₹121, the IPO is set for 20% listing gains after a blockbuster 93.72 times subscription. Get all the live details.
Sudeep Pharma shares list on BSE and NSE today after 93.72 times subscription. Grey market signals 20% premium debut. Full details on pricing and investor response.
Sudeep Pharma IPO makes Dalal Street debut on November 28. Grey market premium hits ₹100, signaling 15% listing gain. Discover subscription details and key facts.
Bokaro police register FIR against Aryan Singh of New Sun Pharma for illegal codeine syrup trade. 32,000 bottles seized. Read the full investigation details.
IMF's latest assessment reveals India's strong economic outlook with 6.6% growth forecast. Discover how prudent policies and structural reforms drive sustained growth and reduce poverty.
Shaily Engineering and Gland Pharma positioned to benefit from India's semaglutide gold rush as patent expiry opens market for generic weight-loss drugs. Discover how these companies are preparing.
Sudeep Pharma IPO allotment finalized today after massive 93.71x subscription. GMP at ₹87 signals 14.67% listing gain. Track your allotment status now!
Sudeep Pharma IPO allotment likely on November 26. Learn how to check allotment status via BSE, NSE, registrar. Strong 93.72x subscription signals investor confidence.